0001140361-15-022956.txt : 20150602
0001140361-15-022956.hdr.sgml : 20150602
20150602202426
ACCESSION NUMBER: 0001140361-15-022956
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150529
FILED AS OF DATE: 20150602
DATE AS OF CHANGE: 20150602
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Relypsa Inc
CENTRAL INDEX KEY: 0001416792
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260893742
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-421-9500
MAIL ADDRESS:
STREET 1: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Orwin John A
CENTRAL INDEX KEY: 0001477384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36184
FILM NUMBER: 15908544
MAIL ADDRESS:
STREET 1: C/O RELYPSA, INC.
STREET 2: 700 SAGINAW DR.
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc1.xml
FORM 4
X0306
4
2015-05-29
0
0001416792
Relypsa Inc
RLYP
0001477384
Orwin John A
C/O RELYPSA, INC.
100 CARDINAL WAY
REDWOOD CITY
CA
94063
1
1
0
0
President & CEO
Common Stock
2015-05-29
4
M
0
20000
7.40
A
55000
D
Common Stock
2015-05-29
4
S
0
14694
36.3953
D
40306
D
Common Stock
2015-05-29
4
S
0
5306
36.9786
D
35000
D
Common Stock
2015-06-01
4
M
0
8555
7.4
A
43555
D
Common Stock
2015-06-01
4
S
0
8351
35.7913
D
35204
D
Common Stock
2015-06-01
4
S
0
5204
36.9437
D
30000
D
Stock Option (right to buy)
7.40
2015-05-29
4
M
0
20000
0.00
D
2023-07-23
Common Stock
20000
811432
D
Stock Option (right to buy)
7.40
2015-06-01
4
M
0
8555
0.00
D
2023-07-23
Common Stock
8555
802877
D
Includes 20,000 restricted stock units.
The sales reported in this Form 4 were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.79 to $36.78, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.79 to $37.18, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from June 17, 2013 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.35 to $36.3327, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.35 to $37.29, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Ronald A. Krasnow, as Attorney-in-Fact for John A. Orwin
2015-06-02